The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1300
Alvimopan (Entereg) for Postoperative Ileus
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the marketing of alvimopan (Entereg – Adolor/GlaxoSmithKline), a selective muopioid receptor antagonist, for oral treatment of postoperative ileus after bowel resection. The only other drug in this class available in the US is subcutaneously injected methylnaltrexone (Relistor), which is approved for treatment of opioid-induced constipation in patients with advanced illness receiving palliative care.1

MECHANISM OF ACTION — Following a bowel resection, postoperative pain management regimens typically include an opioid, which is one of the causes of postoperative ileus. Taken orally, alvimopan blocks the gastrointestinal (GI) effects of opioids by binding to mu-opioid receptors in the GI tract. It does not interfere with the central analgesic effects of these drugs.

PHARMACOKINETICS — Alvimopan is poorly absorbed from the GI tract, with ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Alvimopan (Entereg) for Postoperative Ileus
Article code: 1300a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian